Skip to content
SPACListing
CompletedNasdaq

Tango Therapeutics, Inc.TNGX

Class A TNGXCIK 0001819133

Cash in trust

$167M

$166,815,023

Trust per share

$10.00

Redemption value

IPO

Sep 2020

$167M raised

Combination deadline

—

Not disclosed

Filings on record

421

Latest Oct 23, 2026

Business combination

Target
Not disclosed in an indexed filing
Announced
Apr 14, 2021
Closed
Aug 13, 2021

Overview

Tango Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001819133. It completed its initial public offering in Sep 2020, raising $167M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker TNGX on Nasdaq. The vehicle is sponsored by BCTG through BCTG Holdings, LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.

“we intend to focus on businesses that have their primary operations located in North America and Europe in the biotechnology industry.”
The mandate, as stated in the IPO prospectus
HealthcareNorth AmericaEurope

Reading the filings

Arithmetic on what Tango Therapeutics, Inc. has disclosed, written the way a desk would read it. These are observations, not a rating. Nothing here scores the vehicle or implies a view on it.

  • Trust versus the $10 unit

    The trust holds $10.00 per public share, effectively the $10.00 the units were sold at, so little or no interest has accrued to the account yet.

  • Underwriting

    SVB Leerink led the offering. It has been named on 3 SPAC IPOs, and 100% of its resolved vehicles closed a deal. The syndicate has no control over whether a sponsor finds a target, but the quality of the book at pricing shapes who ends up holding the units.

How busy it has been

Filings per month since the first one. A vehicle that has gone quiet with a deadline ahead is a different proposition from one that is still working.

191002020-072026-10

421 filings in all. 19 in the last three months, against a busiest month of 19.

News on Tango Therapeutics, Inc.

Last 90 days

News sentiment

Neutral
negativeneutralpositive

Across 12 recent stories, weighted towards the newest. Scored by our own headline classifier using finance- and SPAC-specific terms. It reads what a story is about, not what the shares are worth.

SEC filing history

Free tier: filings older than 24 hours
  • 8-K

    Regulation FD disclosure; Other events

    Items 7.01, 8.01, 9.01 · Accession 0001193125-26-429423

    Oct 23, 2026

    2d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-414500

    Oct 5, 2026

    20d ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-401327

    Sep 24, 2026

    1mo ago

    View on EDGAR ↗
  • 144

    144 filing

    Accession 0001950047-26-009747

    Sep 22, 2026

    1mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-381853

    Sep 3, 2026

    1mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001916761-26-000008

    Aug 14, 2026

    2mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0001193125-26-352271

    Aug 14, 2026

    2mo ago

    View on EDGAR ↗
  • SCHEDULE 13G

    Beneficial ownership report (passive)

    Accession 0000886982-26-000510

    Aug 14, 2026

    2mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000919574-26-005265

    Aug 14, 2026

    2mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000908834-26-000425

    Aug 14, 2026

    2mo ago

    View on EDGAR ↗
  • SCHEDULE 13G/A

    Amended beneficial ownership report (passive)

    Accession 0000919574-26-004954

    Aug 12, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K

    Other events

    Items 8.01, 9.01 · Accession 0001193125-26-344997

    Aug 11, 2026

    2mo ago

    View on EDGAR ↗
  • 424B5

    424B5

    Accession 0001193125-26-344989

    Aug 11, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Items 2.02, 9.01 · Accession 0001193125-26-343434

    Aug 11, 2026

    2mo ago

    View on EDGAR ↗
  • 10-Q

    Quarterly report

    Accession 0001193125-26-343424

    Aug 11, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K/A

    Regulation FD disclosure

    Items 5.02, 7.01, 9.01 · Accession 0001193125-26-339070

    Aug 7, 2026

    2mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Item 5.02 · Accession 0001193125-26-338480

    Aug 6, 2026

    2mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-335002

    Aug 5, 2026

    2mo ago

    View on EDGAR ↗
  • 144

    144 filing

    Accession 0001950047-26-007562

    Aug 3, 2026

    2mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-295124

    Jul 2, 2026

    3mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-279871

    Jun 23, 2026

    4mo ago

    View on EDGAR ↗
  • 3

    Initial statement of beneficial ownership

    Accession 0001193125-26-279866

    Jun 23, 2026

    4mo ago

    View on EDGAR ↗
  • 8-K

    Current report

    Items 5.02, 9.01 · Accession 0001193125-26-279788

    Jun 23, 2026

    4mo ago

    View on EDGAR ↗
  • 144

    144 filing

    Accession 0001894038-26-000002

    Jun 17, 2026

    4mo ago

    View on EDGAR ↗
  • 144

    144 filing

    Accession 0001950047-26-005968

    Jun 11, 2026

    4mo ago

    View on EDGAR ↗
  • 8-K

    Entry into a material definitive agreement

    Items 1.01, 9.01 · Accession 0001193125-26-266078

    Jun 10, 2026

    4mo ago

    View on EDGAR ↗
  • 424B5

    424B5

    Accession 0001193125-26-266074

    Jun 10, 2026

    4mo ago

    View on EDGAR ↗
  • 144

    144 filing

    Accession 0001950047-26-005901

    Jun 10, 2026

    4mo ago

    View on EDGAR ↗
  • FWP

    FWP

    Accession 0001193125-26-264555

    Jun 10, 2026

    4mo ago

    View on EDGAR ↗
  • 4

    Statement of changes in beneficial ownership

    Accession 0001193125-26-262227

    Jun 8, 2026

    4mo ago

    View on EDGAR ↗

Pro

Track TNGX without the delay

Free accounts see this filing history a day late. Pro shows every document minutes after EDGAR publishes it, opens it on EDGAR in one click, and adds the twelve-month deadline calendar.

  • Filings live, no 24-hour delay
  • One click through to the source document
  • Deadline calendar out to 12 months
  • CSV export, API and MCP access

Cancel any time. Billed monthly in USD.

Tango Therapeutics, Inc.: questions answered

What is Tango Therapeutics, Inc. (TNGX)?

Tango Therapeutics, Inc. is a special purpose acquisition company incorporated in Delaware and registered with the SEC under CIK 0001819133. It completed its initial public offering in Sep 2020, raising $167M in gross proceeds and listing on Nasdaq. Class A shares trade under the ticker TNGX on Nasdaq. The vehicle is sponsored by BCTG through BCTG Holdings, LLC. The mandate targets healthcare. Business combination closed; the company trades under a new ticker.

How much does Tango Therapeutics, Inc. hold in trust?

Approximately $166,815,023, or about $10.00 per public share, as at the most recent filing on record. Trust balances move: shareholders redeem at extension votes and at the combination vote, and sponsors pay contributions in to extend. Treat the figure as a point-in-time disclosure, not a running balance.

When must Tango Therapeutics, Inc. complete a merger?

No combination deadline appears in the filings we have indexed. The date is stated in the charter and repeated in each quarterly report; where our parser could not establish it with confidence we leave it blank rather than infer one.

What happens if Tango Therapeutics, Inc. does not find a target in time?

The charter requires the vehicle to redeem 100% of the public shares and return the trust, pro rata, to public shareholders. That is the mechanism working as designed rather than a default. Founder shares and warrants are worthless in that outcome, which is why the sponsor's incentive is to get a deal done or to buy more time. Across the market, deadline lapsed without a deal; trust returned to public shareholders.

Can I redeem shares in Tango Therapeutics, Inc., and at what price?

Public shareholders may elect to redeem in connection with a combination vote and at each extension vote, at the pro-rata trust value on the relevant record date, most recently disclosed at about $10.00 per share. Redemption is a right attached to the public shares only; warrants and rights carry no claim on the trust. The mechanics and the deadline for electing are set out in the proxy statement for the vote in question.

What tickers does Tango Therapeutics, Inc. trade under?

Class A shares trade as TNGX on Nasdaq. Units trade first and separate into their component securities roughly 52 days after the IPO; only the Class A shares carry the redemption right against the trust.

Is the trust value the same as the share price for Tango Therapeutics, Inc.?

No, and the gap between them is the whole trade. Trust per share is a disclosed, contractual figure of $10.00, being what a redeeming holder receives. The market price is whatever the shares change hands at: most recently $23.34, a spread to the redemption value. Quotes on this site are delayed and indicative; confirm on your own venue before trading.

Who sponsors Tango Therapeutics, Inc., and what is their track record?

BCTG Holdings, LLC is the sponsor entity, part of the BCTG franchise. This is the only vehicle we have attributed to that sponsor. Named principals: Aaron Davis.

Which banks underwrote the Tango Therapeutics, Inc. IPO?

SVB Leerink. Syndicate membership and role are read from the prospectus cover and the underwriting section.

Is Tango Therapeutics, Inc. tradeable, and where?

Yes. TNGX returned a live quote of $23.34 on Nasdaq. Quotes here are delayed and refreshed on a schedule rather than streamed, so treat the figure as indicative and confirm on your own venue. Units and warrants trade under their own symbols and are quoted separately.

Is Tango Therapeutics, Inc. a good investment?

That is not a question this site answers. Tango Therapeutics, Inc. is covered here as reference data: what the company filed, when it filed it, and what the numbers in those filings say. The Edge, FOMO and Potential scores on this page are derived measures with a published formula, not ratings of investment merit: they describe the setup, and every component is shown so you can take them apart. We publish no price targets and no recommendations, and nothing here should be read as advice. The figures are a starting point for your own work, and each one carries the accession number of the filing it came from.

Where does this Tango Therapeutics, Inc. data come from?

Filings Tango Therapeutics, Inc. submitted to the SEC under CIK 0001819133: the registration statement and final prospectus for the structure, quarterly and annual reports for the trust, current reports and proxy statements for deals, votes and extensions. Trust economics are taken from the registrant's own XBRL tags rather than parsed from prose, which is why they are exact. Every filing in the history above is listed with its accession number, which identifies the document uniquely on EDGAR; Pro accounts open it directly from the row.

Compiled by the SPACListing research desk

Last reconciled Oct 25, 2026

Every figure on this page is read from documents the registrants filed with the U.S. Securities and Exchange Commission, principally the IPO prospectus (Form 424B4), quarterly and annual reports, current reports and proxy statements, the registrant's own XBRL tags for trust economics. Nothing is sourced from press coverage, from the companies themselves, or from a third-party aggregator. Where a filing does not disclose something, the field is left blank rather than estimated.

Read the full methodology · What is in the dataset · Report a correction

SPACListing is a reference-data service, not an investment adviser. Nothing here is a recommendation to buy or sell any security.

Continue reading

The context around this vehicle: who else the sponsor has launched, which banks priced it, and where it sits in the wider market.